Fungal biofilms, drug resistance, and recurrent infection

Cold Spring Harbor Perspectives in Medicine

Volumn 4, Issue 10, 2014, Pages

  Desai, Jigar V ^a   Mitchell, Aaron P ^a   Andes, David R ^b  

^a CARNEGIE MELLON UNIVERSITY   (United States)

^b UNIVERSITY OF WISCONSIN SCHOOL OF MEDICINE AND PUBLIC HEALTH   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIFUNGAL AGENT; GLUCAN;

ANTIFUNGAL RESISTANCE; ARTICLE; ASPERGILLUS; BIOFILM; CANDIDA; EXTRACELLULAR MATRIX; GENETIC REGULATION; GENOMICS; HUMAN; RECURRENT INFECTION; ASPERGILLUS FUMIGATUS; CANDIDA ALBICANS; COINFECTION; DRUG EFFECTS; GENETICS; GROWTH, DEVELOPMENT AND AGING; METABOLISM; MICROBIOLOGY; MYCOSES; PHYSIOLOGY; PROSTHESIS-RELATED INFECTIONS; RECURRENT DISEASE;

FUNGI;

ASPERGILLUS FUMIGATUS; BIOFILMS; CANDIDA ALBICANS; COINFECTION; DRUG RESISTANCE, FUNGAL; EXTRACELLULAR MATRIX; GLUCANS; HUMANS; MYCOSES; PROSTHESIS-RELATED INFECTIONS; RECURRENCE;

EID: 84923780897     PISSN: None     EISSN: 21571422     Source Type: Journal    
DOI: 10.1101/cshperspect.a019729     Document Type: Article

References (129)

1. Albuquerque P, Nicola AM, Nieves E, Paes HC, Williamson PR, Silva-Pereira I, Casadevall A. 2013.Quorum sensingmediated, cell density-dependent regulation of growth and virulence in Cryptococcus neoformans. MBio 5: e00986-13.
2. Al-Fattani MA, Douglas LJ. 2004. Penetration of Candida biofilms by antifungal agents. Antimicrob Agents Chemother 48: 3291-3297.
3. Al-Fattani MA, Douglas LJ. 2006. Biofilm matrix of Candida albicans and Candida tropicalis: Chemical composition and role in drug resistance. J Med Microbiol 55: 999-1008.
4. Almeida RS, Wilson D, Hube B. 2009. Candida albicans iron acquisition within the host. FEMS Yeast Res 9: 1000-1012.
5. Andes D, Nett J, Oschel P, Albrecht R, Marchillo K, Pitula A. 2004. Development and characterization of an in vivo central venous catheter Candida albicans biofilm model. Infect Immun 72: 6023-6031.
6. Baillie GS, Douglas LJ. 2000. Matrix polymers of Candida biofilms and their possible role in biofilm resistance to antifungal agents. J Antimicrob Chemother 46: 397-403.
7. Banerjee U, Gupta K, Venugopal P. 1997. Acase of prosthetic valve endocarditis caused by Cryptococcus neoformans var. neoformans. J Med Vet Mycol 35: 139-141.
8. Beauvais A, Schmidt C, Guadagnini S, Roux P, Perret E, Henry C, Paris S, Mallet A, Prevost MC, Latge JP. 2007. An extracellular matrix glues together the aerial-grown hyphae of Aspergillus fumigatus. Cell Microbiol 9: 1588-1600.
9. Bink A, Vandenbosch D, Coenye T, Nelis H, Cammue BP, Thevissen K. 2011. Superoxide dismutases are involved in Candida albicans biofilm persistence against miconazole. Antimicrob Agents Chemother 55: 4033-4037.
10. Bonfante L, Nalesso F, Cara M, Antonello A, Malagoli A, Pastori G, Guizzo M, D’Angelo A, Gambaro G. 2005. Aspergillus fumigatus peritonitis in ambulatory peritoneal dialysis: A case report and notes on the therapeutic approach. Nephrology (Carlton) 10: 270-273.
11. Bonhomme J, d’Enfert C. 2013. Candida albicans biofilms: Building a heterogeneous, drug-tolerant environment. Curr Opin Microbiol 16: 398-403.
12. Bonhomme J, Chauvel M, Goyard S, Roux P, Rossignol T, d’Enfert C. 2011. Contribution of the glycolytic flux and hypoxia adaptation to efficient biofilm formation by Candida albicans. Mol Microbiol 80: 995-1013.
13. Braun DK, Janssen DA, Marcus JR, Kauffman CA. 1994. Cryptococcal infection of a prosthetic dialysis fistula. Am J Kidney Dis 24: 864-867.
14. Bugli F, Posteraro B, Papi M, Torelli R, Maiorana A, Paroni Sterbini F, Posteraro P, Sanguinetti M, De Spirito M. 2013. In vitro interaction between alginate lyase and amphotericin B against Aspergillus fumigatus biofilm determined by different methods. Antimicrob Agents Chemother 57: 1275-1282.
15. Cao YY, Cao YB, Xu Z, Ying K, Li Y, Xie Y, Zhu ZY, ChenWS, Jiang YY. 2005. cDNA microarray analysis of differential gene expression in Candida albicans biofilm exposed to farnesol. Antimicrob Agents Chemother 49: 584-589.
16. Carlson E. 1982. Synergistic effect of Candida albicans and Staphylococcus aureus on mouse mortality. Infect Immun 38: 921-924.
17. Chandra J, Kuhn DM, Mukherjee PK, Hoyer LL, McCormick T, Ghannoum MA. 2001. Biofilm formation by the fungal pathogen Candida albicans: Development, architecture, and drug resistance. J Bacteriol 183: 5385-5394.
18. Connolly LA, Riccombeni A, Grozer Z, Holland LM, Lynch DB, Andes DR, Gacser A, Butler G. 2013. The APSES transcription factor Efg1 is a global regulator that controls morphogenesis and biofilm formation in Candida parapsilosis. Mol Microbiol 90: 36-53.
19. Costerton JW, Stewart PS, Greenberg EP. 1999. Bacterial biofilms: A common cause of persistent infections. Science 284: 1318-1322.
20. Cugini C, Calfee MW, Farrow JM, Morales DK, Pesci EC, Hogan DA. 2007. Farnesol, a common sesquiterpene, inhibits PQS production in Pseudomonas aeruginosa. Mol Microbiol 65: 896-906.
21. Cushion MT, Collins MS, Linke MJ. 2009. Biofilm formation by Pneumocystis spp. Eukaryot Cell 8: 197-206.
22. Daniels KJ, Park YN, Srikantha T, Pujol C, Soll DR. 2013. Impact of environmental conditions on the form and function of Candida albicans biofilms. Eukaryot Cell 12: 1389-1402.
23. Darouiche RO. 2001. Device-associated infections: A macroproblem that starts with microadherence. Clin Infect Dis 33: 1567-1572.
24. Davies DG, Parsek MR, Pearson JP, Iglewski BH, Costerton JW, Greenberg EP. 1998. The involvement of cell-to-cell signals in the development of a bacterial biofilm. Science 280: 295-298.
25. Davis-Hanna A, Piispanen AE, Stateva LI, Hogan DA. 2008. Farnesol and dodecanol effects on the Candida albicans Ras1-cAMP signalling pathway and the regulation of morphogenesis. Mol Microbiol 67: 47-62.
26. Desai JV, Bruno VM, Ganguly S, Stamper RJ, Mitchell KF, Solis N, Hill EM, Xu W, Filler SG, Andes DR, et al. 2013. Regulatory role of glycerol in Candida albicans biofilm formation. MBio 4: e00637-12.
27. Di Bonaventura G, Pompilio A, Picciani C, Iezzi M, D’Antonio D, Piccolomini R. 2006. Biofilm formation by the emerging fungal pathogen Trichosporon asahii: Development, architecture, and antifungal resistance. Antimicrob Agents Chemother 50: 3269-3276.
28. Ding C, Butler G. 2007. Development of a gene knockout system in Candida parapsilosis reveals a conserved role for BCR1 in biofilm formation. Eukaryot Cell 6: 1310-1319.
29. Ding C, Vidanes GM, Maguire SL, Guida A, Synnott JM, Andes DR, Butler G. 2011. Conserved and divergent roles of Bcr1 and CFEM proteins in Candida parapsilosis and Candida albicans. PLoS ONE 6: e28151.
30. Dongari-Bagtzoglou A. 2008. Pathogenesis of mucosal biofilm infections: Challenges and progress. Expert Rev Anti Infect Ther 6: 201-208.
31. Donlan RM. 2001. Biofilms and device-associated infections. Emerg Infect Dis 7: 277-281.
32. Donlan RM. 2002. Biofilms: Microbial life on surfaces. Emerg Infect Dis 8: 881-890.
33. Donlan RM, Costerton JW. 2002. Biofilms: Survival mechanisms of clinically relevant microorganisms. Clin Microbiol Rev 15: 167-193.
34. Fanning S, Mitchell AP. 2012. Fungal biofilms. PLoS Pathog 8: e1002585.
35. Fanning S, Xu W, Beaurepaire C, Suhan JP, Nantel A, Mitchell AP. 2012a. Functional control of the Candida albicans cell wall by catalytic protein kinase A subunit Tpk1. Mol Microbiol 86: 284-302.
36. Fanning S, Xu W, Solis N, Woolford CA, Filler SG, Mitchell AP. 2012b. Divergent targets of Candida albicans biofilm regulator Bcr1 in vitro and in vivo. Eukaryot Cell 11: 896-904.
37. Finkel JS, Mitchell AP. 2011. Genetic control of Candida albicans biofilm development. Nat Rev Microbiol 9: 109-118.
38. Finkel JS, Xu W, Huang D, Hill EM, Desai JV, Woolford CA, Nett JE, Taff H, Norice CT, Andes DR, et al. 2012. Portrait of Candida albicans adherence regulators. PLoS Pathog 8: e1002525.
39. Flemming HC, Wingender J. 2010. The biofilm matrix. Nat Rev Microbiol 8: 623-633.
40. Ganguly S, Mitchell AP. 2011. Mucosal biofilms of Candida albicans. Curr Opin Microbiol 14: 380-385.
41. Ganguly S, Bishop AC, Xu W, Ghosh S, Nickerson KW, Lanni F, Patton-Vogt J, Mitchell AP. 2011. Zap1 control of cell-cell signaling in Candida albicans biofilms. Eukaryot Cell 10: 1448-1454.
42. Garcia-Sanchez S, Aubert S, Iraqui I, Janbon G, Ghigo JM, d’Enfert C. 2004. Candida albicans biofilms: A developmental state associated with specific and stable gene expression patterns. Eukaryot Cell 3: 536-545.
43. Gibbons JG, Beauvais A, Beau R, McGary KL, Latge JP, Rokas A. 2012. Global transcriptome changes underlying colony growth in the opportunistic human pathogen Aspergillus fumigatus. Eukaryot Cell 11: 68-78.
44. Gravelat FN, Beauvais A, Liu H, Lee MJ, Snarr BD, Chen D, Xu W, Kravtsov I, Hoareau CM, Vanier G, et al. 2013. Aspergillus galactosaminogalactan mediates adherence to host constituents and conceals hyphal b-glucan from the immune system. PLoS Pathog 9: e1003575.
45. Hall RA, Turner KJ, Chaloupka J, Cottier F, De Sordi L, Sanglard D, Levin LR, Buck J, Muhlschlegel FA. 2011. The quorum-sensing molecules farnesol/homoserine lactone and dodecanol operate via distinct modes of action in Candida albicans. Eukaryot Cell 10: 1034-1042.
46. Hall-Stoodley L, Costerton JW, Stoodley P. 2004. Bacterial biofilms: From the natural environment to infectious diseases. Nat Rev Microbiol 2: 95-108.
47. Harriott MM, Noverr MC. 2009. Candida albicans and Staphylococcus aureus form polymicrobial biofilms: Effects on antimicrobial resistance. Antimicrob Agents Chemother 53: 3914-3922.
48. Harriott MM, Noverr MC. 2011. Importance of Candidabacterial polymicrobial biofilms in disease. TrendsMicrobiol 19: 557-563.
49. Harriott MM, Lilly EA, Rodriguez TE, Fidel PL Jr, Noverr MC. 2010. Candida albicans forms biofilms on the vaginal mucosa. Microbiology 156: 3635-3644.
50. Hawser SP, Douglas LJ. 1994. Biofilm formation by Candida species on the surface of catheter materials in vitro. Infect Immun 62: 915-921.
51. Hawser SP, Baillie GS, Douglas LJ. 1998. Production of extracellular matrix by Candida albicans biofilms. J Med Microbiol 47: 253-256.
52. Jabra-Rizk MA, Meiller TF, James CE, Shirtliff ME. 2006. Effect of farnesol on Staphylococcus aureus biofilm formation and antimicrobial susceptibility. Antimicrob Agents Chemother 50: 1463-1469.
53. Jeloka TK, Shrividya S, Wagholikar G. 2011. Catheter outflow obstruction due to an aspergilloma. Perit Dial Int 31: 211-212.
54. Johnson CC, Yu A, Lee H, Fidel PL Jr, Noverr MC. 2012. Development of a contemporary animal model of Candida albicans-associated denture stomatitis using a novel intraoral denture system. Infect Immun 80: 1736-1743.
55. Kojic EM, Darouiche RO. 2004. Candida infections of medical devices. Clin Microbiol Rev 17: 255-267.
56. Kolter R, Greenberg EP. 2006. Microbial sciences: The superficial life of microbes. Nature 441: 300-302.
57. Krzossok S, Birck R, Henke S, Hof H, van der Woude FJ, Braun C. 2004. Trichosporon asahii infection of a dialysis PTFE arteriovenous graft. Clin Nephrol 62: 66-68.
58. Kucharikova S, Tournu H, Lagrou K, Van Dijck P, Bujdakova H. 2011. Detailed comparison of Candida albicans and Candida glabrata biofilms under different conditions and their susceptibility to caspofungin and anidulafungin. J Med Microbiol 60: 1261-1269.
59. Kuhn DM, Ghannoum MA. 2004. Candida biofilms: Antifungal resistance and emerging therapeutic options. Curr Opin Investig Drugs 5: 186-197.
60. Kumamoto CA, Vinces MD. 2005. Alternative Candida albicans lifestyles: Growth on surfaces. Annu Rev Microbiol 59: 113-133.
61. LaFleur MD, Kumamoto CA, Lewis K. 2006. Candida albicans biofilms produce antifungal-tolerant persister cells. Antimicrob Agents Chemother 50: 3839-3846.
62. Lattif AA, Mukherjee PK, Chandra J, Swindell K, Lockhart SR, Diekema DJ, Pfaller MA, Ghannoum MA. 2010. Characterization of biofilms formed by Candida parapsilosis, C. metapsilosis, and C. orthopsilosis. Int J Med Microbiol 300: 265-270.
63. Lewis K. 2010. Persister cells. Annu Rev Microbiol 64: 357-372.
64. Lewis RE, Lo HJ, Raad II, Kontoyiannis DP. 2002. Lack of catheter infection by the efg1/efg1 cph1/cph1 doublenull mutant, a Candida albicans strain that is defective in filamentous growth. Antimicrob Agents Chemother 46: 1153-1155.
65. Loussert C, Schmitt C, Prevost MC, Balloy V, Fadel E, Philippe B, Kauffmann-Lacroix C, Latge JP, Beauvais A. 2010. In vivo biofilm composition of Aspergillus fumigatus. Cell Microbiol 12: 405-410.
66. Lynch AS, Robertson GT. 2008. Bacterial and fungal biofilm infections. Annu Rev Med 59: 415-428.
67. Madhani HD. 2011. Quorum sensing in fungi: Q&A. PLoS Pathog 7: e1002301.
68. Martinez LR, Casadevall A. 2007. Cryptococcus neoformans biofilm formation depends on surface support and carbon source and reduces fungal cell susceptibility to heat, cold, and UV light. Appl Environ Microbiol 73: 4592-4601.
69. Martinez LR, Fries BC. 2010. Fungal biofilms: Relevance in the setting of human disease. Curr Fungal Infect Rep 4: 266-275.
70. Martins M, Uppuluri P, Thomas DP, Cleary IA, Henriques M, Lopez-Ribot JL, Oliveira R. 2010. Presence of extracellular DNA in the Candida albicans biofilm matrix and its contribution to biofilms. Mycopathologia 169: 323-331.
71. Martins M, Henriques M, Lopez-Ribot JL, Oliveira R. 2012. Addition of DNase improves the in vitro activity of antifungal drugs against Candida albicans biofilms. Mycoses 55: 80-85.
72. McDonagh A, Fedorova ND, Crabtree J, Yu Y, Kim S, Chen D, Loss O, Cairns T, Goldman G, Armstrong-James D, et al. 2008. Sub-telomere directed gene expression during initiation of invasive aspergillosis. PLoS Pathog 4: e1000154.
73. Mitchell AP. 1994. Control of meiotic gene expression in Saccharomyces cerevisiae. Microbiol Rev 58: 56-70.
74. Mitchell KF, Taff HT, Cuevas MA, Reinicke EL, Sanchez H, Andes DR. 2013. Role of matrix b-1,3 glucan in antifungal resistance of non-albicans Candida biofilms. Antimicrob Agents Chemother 57: 1918-1920.
75. Morales DK, Hogan DA. 2010. Candida albicans interactions with bacteria in the context of human health and disease. PLoS Pathog 6: e1000886.
76. Mowat E, Williams C, Jones B, McChlery S, Ramage G. 2009. The characteristics of Aspergillus fumigatus mycetoma development: Is this a biofilm? Med Mycol 47 (Suppl 1): S120-S126.
77. Mukherjee PK, Chandra J, Kuhn DM, Ghannoum MA. 2003. Mechanism of fluconazole resistance in Candida albicans biofilms: Phase-specific role of efflux pumps and membrane sterols. Infect Immun 71: 4333-4340.
78. Murillo LA, Newport G, Lan CY, Habelitz S, Dungan J, Agabian NM. 2005. Genome-wide transcription profiling of the early phase of biofilm formation by Candida albicans. Eukaryot Cell 4: 1562-1573.
79. Muszkieta L, Beauvais A, Pahtz V, Gibbons JG, Anton Leberre V, Beau R, Shibuya K, Rokas A, Francois JM, Kniemeyer O, et al. 2013. Investigation of Aspergillus fumigatus biofilm formation by various “omics” approaches. Front Microbiol 4: 13.
80. Nett J, Andes D. 2006. Candida albicans biofilm development, modeling a host-pathogen interaction. Curr Opin Microbiol 9: 340-345.
81. Nett J, Lincoln L, Marchillo K, Massey R, Holoyda K, Hoff B, VanHandel M, Andes D. 2007. Putative role of b-1,3 glucans in Candida albicans biofilm resistance. Antimicrob Agents Chemother 51: 510-520.
82. Nett JE, Crawford K, Marchillo K, Andes DR. 2010a. Role of Fks1p and matrix glucan in Candida albicans biofilm resistance to an echinocandin, pyrimidine, and polyene. Antimicrob Agents Chemother 54: 3505-3508.
83. Nett JE, Sanchez H, Cain MT, Andes DR. 2010b. Genetic basis of Candida biofilm resistance due to drug-sequestering matrix glucan. J Infect Dis 202: 171-175.
84. Nett JE, Sanchez H, Cain MT, Ross KM, Andes DR. 2011. Interface of Candida albicans biofilm matrix-associated drug resistance and cell wall integrity regulation. Eukaryot Cell 10: 1660-1669.
85. Nickerson KW, Atkin AL, Hornby JM. 2006. Quorum sensing in dimorphic fungi: Farnesol and beyond. Appl Environ Microbiol 72: 3805-3813.
86. Nobbs AH, Vickerman MM, Jenkinson HF. 2010. Heterologous expression of Candida albicans cell wall-associated adhesins in Saccharomyces cerevisiae reveals differential specificities in adherence and biofilm formation and in binding oral Streptococcus gordonii. Eukaryot Cell 9: 1622-1634.
87. Nobile CJ, Mitchell AP. 2005. Regulation of cell-surface genes and biofilm formation by the C. albicans transcription factor Bcr1p. Curr Biol 15: 1150-1155.
88. Nobile CJ, Andes DR, Nett JE, Smith FJ, Yue F, Phan QT, Edwards JE, Filler SG, Mitchell AP. 2006. Critical role of Bcr1-dependent adhesins in C. albicans biofilm formation in vitro and in vivo. PLoS Pathog 2: e63.
89. Nobile CJ, Nett JE, Hernday AD, Homann OR, Deneault JS, Nantel A, Andes DR, Johnson AD, Mitchell AP. 2009. Biofilm matrix regulation by Candida albicans Zap1. PLoS Biol 7: e1000133.
90. Nobile CJ, Fox EP, Nett JE, Sorrells TR, Mitrovich QM, Hernday AD, Tuch BB, Andes DR, Johnson AD. 2012. A recently evolved transcriptional network controls biofilm development in Candida albicans. Cell 148: 126-138.
91. O’Toole GA. 2003. To build a biofilm. J Bacteriol 185: 2687-2689.
92. Pannanusorn S, Fernandez V, Romling U. 2013a. Prevalence of biofilm formation in clinical isolates of Candida species causing bloodstream infection. Mycoses 56: 264-272.
93. Pannanusorn S, Ramirez-Zavala B, Lunsdorf H, Agerberth B, Morschhauser J, Romling U. 2013b. Characterization of biofilm formation and the role of BCR1 in clinical isolates of Candida parapsilosis. Eukaryot Cell 13: 438-451.
94. Park YN, Daniels KJ, Pujol C, Srikantha T, Soll DR. 2013. Candida albicans forms a specialized “sexual” as well as “pathogenic” biofilm. Eukaryot Cell 12: 1120-1131.
95. Paulitsch AH, Willinger B, Zsalatz B, Stabentheiner E, Marth E, Buzina W. 2009. In vivo Candida biofilms in scanning electron microscopy. Med Mycol 47: 690-696.
96. Peleg AY, Hogan DA, Mylonakis E. 2010. Medically important bacterial-fungal interactions. Nat Rev Microbiol 8: 340-349.
97. Peters BM, Jabra-Rizk MA, O’May GA, Costerton JW, Shirtliff ME. 2012a. Polymicrobial interactions: Impact on pathogenesis and human disease. Clin Microbiol Rev 25: 193-213.
98. Peters BM, Ovchinnikova ES, Krom BP, Schlecht LM, Zhou H, Hoyer LL, Busscher HJ, van der Mei HC, Jabra-Rizk MA, Shirtliff ME. 2012b. Staphylococcus aureus adherence to Candida albicans hyphae is mediated by the hyphal adhesin Als3p. Microbiology 158: 2975-2986.
99. Raad I. 1998. Intravascular-catheter-related infections. Lancet 351: 893-898.
100. Rajendran R, Williams C, Lappin DF, Millington O, Martins M, Ramage G. 2013. Extracellular DNA release acts as an antifungal resistance mechanism in mature Aspergillus fumigatus biofilms. Eukaryot Cell 12: 420-429.
101. Ramage G, VandeWalle K, Wickes BL, Lopez-Ribot JL. 2001. Biofilm formation by Candida dubliniensis. J Clin Microbiol 39: 3234-3240.
102. Ramage G, Saville SP, Wickes BL, Lopez-Ribot JL. 2002a. Inhibition of Candida albicans biofilm formation by farnesol, a quorum-sensing molecule. Appl Environ Microbiol 68: 5459-5463.
103. Ramage G, VandeWalle K, Lopez-Ribot JL, Wickes BL. 2002b. The filamentation pathway controlled by the Efg1 regulator protein is required for normal biofilm formation and development in Candida albicans. FEMS Microbiol Lett 214: 95-100.
104. Ramage G, Saville SP, Thomas DP, Lopez-Ribot JL. 2005. Candida biofilms: An update. Eukaryot Cell 4: 633-638.
105. Ramage G, Martinez JP, Lopez-Ribot JL. 2006. Candida biofilms on implanted biomaterials: A clinically significant problem. FEMS Yeast Res 6: 979-986.
106. Ramage G, Rajendran R, Gutierrez-Correa M, Jones B, Williams C. 2011. Aspergillus biofilms: Clinical and industrial significance. FEMS Microbiol Lett 324: 89-97.
107. Reddy BT, Torres HA, Kontoyiannis DP. 2002. Breast implant infection caused by Trichosporon beigelii. Scand J Infect Dis 34: 143-144.
108. Richard ML, Nobile CJ, Bruno VM, Mitchell AP. 2005. Candida albicans biofilm-defective mutants. Eukaryot Cell 4: 1493-1502.
109. Robbins N, Uppuluri P, Nett J, Rajendran R, Ramage G, Lopez-Ribot JL, Andes D, Cowen LE. 2011. Hsp90 governs dispersion and drug resistance of fungal biofilms. PLoS Pathog 7: e1002257.
110. Rossignol T, Ding C, Guida A, d’Enfert C, Higgins DG, Butler G. 2009. Correlation between biofilm formation and the hypoxic response in Candida parapsilosis. Eukaryot Cell 8: 550-559.
111. Sahni N, Yi S, Daniels KJ, Huang G, Srikantha T, Soll DR. 2010. Tec1 mediates the pheromone response of the white phenotype of Candida albicans: Insights into the evolution of new signal transduction pathways. PLoS Biol 8: e1000363.
112. Samaranayake YH, Ye J, Yau JY, Cheung BP, Samaranayake LP. 2005. In vitro method to study antifungal perfusion in Candida biofilms. J Clin Microbiol 43: 818-825.
113. Shopova I, Bruns S, Thywissen A, Kniemeyer O, Brakhage AA, Hillmann F. 2013. Extrinsic extracellular DNA leads to biofilm formation and colocalizes with matrix polysaccharides in the human pathogenic fungus Aspergillus fumigatus. Front Microbiol 4: 141.
114. Si H, Hernday AD, Hirakawa MP, Johnson AD, Bennett RJ. 2013. Candida albicans white and opaque cells undergo distinct programs of filamentous growth. PLoS Pathog 9: e1003210.
115. Silva S, Henriques M, Martins A, Oliveira R, Williams D, Azeredo J. 2009. Biofilms of non-Candida albicans Candida species: Quantification, structure and matrix composition. Med Mycol 47: 681-689.
116. Silva S, Negri M, Henriques M, Oliveira R, Williams DW, Azeredo J. 2011. Adherence and biofilm formation of non-Candida albicans Candida species. Trends Microbiol 19: 241-247.
117. Srikantha T, Daniels KJ, Pujol C, Kim E, Soll DR. 2013. Identification of genes upregulated by the transcription factor Bcr1 that are involved in impermeability, impenetrability, and drug resistance of Candida albicans a/a biofilms. Eukaryot Cell 12: 875-888.
118. Srinivasan A, Leung KP, Lopez-Ribot JL, Ramasubramanian AK. 2013. High-throughput nano-biofilm microarray for antifungal drug discovery. MBio 4: pii: e00331-13.
119. Stichternoth C, Ernst JF. 2009. Hypoxic adaptation by Efg1 regulates biofilm formation by Candida albicans. Appl Environ Microbiol 75: 3663-3672.
120. Taff HT, Nett JE, Zarnowski R, Ross KM, Sanchez H, Cain MT, Hamaker J, Mitchell AP, Andes DR. 2012. ACandida biofilm-induced pathway for matrix glucan delivery: Implications for drug resistance. PLoS Pathog 8: e1002848.
121. Thomas DP, Bachmann SP, Lopez-Ribot JL. 2006. Proteomics for the analysis of the Candida albicans biofilm lifestyle. Proteomics 6: 5795-5804.
122. Uppuluri P, Chaturvedi AK, Srinivasan A, Banerjee M, Ramasubramaniam AK, Kohler JR, Kadosh D, Lopez-Ribot JL. 2010. Dispersion as an important step in the Candida albicans biofilm developmental cycle. PLoS Pathog 6: e1000828.
123. Vediyappan G, Rossignol T, d’Enfert C. 2010. Interaction of Candida albicans biofilms with antifungals: Transcriptional response and binding of antifungals to b-glucans. Antimicrob Agents Chemother 54: 2096-2111.
124. Walsh TJ, Schlegel R, Moody MM, Costerton JW, Salcman M. 1986. Ventriculoatrial shunt infection due to Cryptococcus neoformans: An ultrastructural and quantitative microbiological study. Neurosurgery 18: 373-375.
125. Wang L, Zhai B, Lin X. 2012. The link between morphotype transition and virulence in Cryptococcus neoformans. PLoS Pathog 8: e1002765.
126. Wang L, Tian X, Gyawali R, Lin X. 2013. Fungal adhesion protein guides community behaviors and autoinduction in a paracrine manner. Proc Natl Acad Sci 110: 11571-11576.
127. Wilking JN, Zaburdaev V, De Volder M, Losick R, Brenner MP, Weitz DA. 2013. Liquid transport facilitated by channels in Bacillus subtilis biofilms. Proc Natl Acad Sci 110: 848-852.
128. Yi S, Sahni N, Daniels KJ, Lu KL, Srikantha T, Huang G, Garnaas AM, Soll DR. 2011. Alternative mating type configurations (a/a versus a/a or a/a) of Candida albicans result in alternative biofilms regulated by different pathways. PLoS Biol 9: e1001117.
129. Zhao X, Daniels KJ, Oh SH, Green CB, Yeater KM, Soll DR, Hoyer LL. 2006. Candida albicans Als3p is required for wild-type biofilm formation on silicone elastomer surfaces. Microbiology 152: 2287-2299.